Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Page 1
Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy-Induced Necrosis.
Ghosh S, Yang R, Duraki D, Zhu J, Kim JE, Jabeen M, Mao C, Dai X, Livezey MR, Boudreau MW, Park BH, Nelson ER, Hergenrother PJ, Shapiro DJ. Ghosh S, et al. Among authors: hergenrother pj. Cancer Res. 2023 Sep 15;83(18):3115-3130. doi: 10.1158/0008-5472.CAN-23-0157. Cancer Res. 2023. PMID: 37522838 Free PMC article.
ErSO induced anticipatory unfolded protein response (a-UPR) hyperactivation, long-term necrotic cell death, and release of damage-associated molecular patterns that activated macrophages and increased monocyte migration, all of which was abolished by TKO. ...
ErSO induced anticipatory unfolded protein response (a-UPR) hyperactivation, long-term necrotic cell death, and release of damage-ass …
Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program.
Janin M, Ortiz-Barahona V, de Moura MC, Martínez-Cardús A, Llinàs-Arias P, Soler M, Nachmani D, Pelletier J, Schumann U, Calleja-Cervantes ME, Moran S, Guil S, Bueno-Costa A, Piñeyro D, Perez-Salvia M, Rosselló-Tortella M, Piqué L, Bech-Serra JJ, De La Torre C, Vidal A, Martínez-Iniesta M, Martín-Tejera JF, Villanueva A, Arias A, Cuartas I, Aransay AM, La Madrid AM, Carcaboso AM, Santa-Maria V, Mora J, Fernandez AF, Fraga MF, Aldecoa I, Pedrosa L, Graus F, Vidal N, Martínez-Soler F, Tortosa A, Carrato C, Balañá C, Boudreau MW, Hergenrother PJ, Kötter P, Entian KD, Hench J, Frank S, Mansouri S, Zadeh G, Dans PD, Orozco M, Thomas G, Blanco S, Seoane J, Preiss T, Pandolfi PP, Esteller M. Janin M, et al. Among authors: hergenrother pj. Acta Neuropathol. 2019 Dec;138(6):1053-1074. doi: 10.1007/s00401-019-02062-4. Epub 2019 Aug 19. Acta Neuropathol. 2019. PMID: 31428936 Free PMC article.
Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease....
Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastati …
Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation.
Peh J, Boudreau MW, Smith HM, Hergenrother PJ. Peh J, et al. Among authors: hergenrother pj. Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4. doi: 10.1016/j.chembiol.2018.05.008. Epub 2018 Jun 14. Cell Chem Biol. 2018. PMID: 29909991 Free PMC article.
However, acquired resistance remains a significant problem in the clinic, limiting the long-term effectiveness of most of these drugs. Here we demonstrate a general strategy to overcome this resistance through drug-induced MEK cleavage (via direct procaspase-3 activation) …
However, acquired resistance remains a significant problem in the clinic, limiting the long-term effectiveness of most of these drugs …
The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.
Peh J, Fan TM, Wycislo KL, Roth HS, Hergenrother PJ. Peh J, et al. Among authors: hergenrother pj. Mol Cancer Ther. 2016 Aug;15(8):1859-69. doi: 10.1158/1535-7163.MCT-16-0025. Epub 2016 Jun 13. Mol Cancer Ther. 2016. PMID: 27297867 Free PMC article.
The development of vemurafenib resistance limits the long-term efficacy of this drug for treatment of metastatic melanomas with the (V600E)BRAF mutation. ...
The development of vemurafenib resistance limits the long-term efficacy of this drug for treatment of metastatic melanomas with the ( …
An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X, Dong Y, Bey EA, Kilgore JA, Bair JS, Li LS, Patel M, Parkinson EI, Wang Y, Williams NS, Gao J, Hergenrother PJ, Boothman DA. Huang X, et al. Among authors: hergenrother pj. Cancer Res. 2012 Jun 15;72(12):3038-47. doi: 10.1158/0008-5472.CAN-11-3135. Epub 2012 Apr 24. Cancer Res. 2012. PMID: 22532167 Free PMC article.
Elevated ROS levels cause extensive DNA lesions, PARP1 hyperactivation, and severe NAD+ /ATP depletion that stimulate Ca2+ -dependent programmed necrosis, unique to this new class of NQO1 "bioactivated" drugs. Short-term exposure of NQO1+ cells to deoxynyboquinone was suff …
Elevated ROS levels cause extensive DNA lesions, PARP1 hyperactivation, and severe NAD+ /ATP depletion that stimulate Ca2+ -dependent progra …